1-Oleoyl lysophosphatidic acid sodium

GMP
Synonyms: 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium
1-Oleoyl lysophosphatidic acid sodium (GMP) 是 GMP 级别的 1-Oleoyl lysophosphatidic acid sodium (MS-G09778),作为可用于细胞疗法的辅助试剂,它本身是一种生物活性脂质信号分子,能抑制 lysoPLD 催化的溶血磷脂酰胆碱和 FS-3 水解反应,并通过激活 LPA1、LPA2 触发钙动员、NFATc1 转位、Rho/ROCK 激活、Smad2/3 磷酸化及 c-Fos 表达,还可诱导类焦虑、类抑郁及运动减少表型,调控破骨细胞细胞骨架与存活能力,降低破骨细胞的骨吸收活性,驱动间充质干细胞向肌成纤维样细胞分化,并刺激转化生长因子-β1 和基质细胞衍生因子-1 的分泌,因此可用于焦虑症、抑郁症及卵巢癌的相关研究。
产品编号: MS-C24371 CAS No.: 325465-93-8 分子式: C21H40NaO7P 分子量: 458.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

1-Oleoyl lysophosphatidic acid sodium (GMP) 是 GMP 级别的 1-Oleoyl lysophosphatidic acid sodium (MS-G09778),作为可用于细胞疗法的辅助试剂,它本身是一种生物活性脂质信号分子,能抑制 lysoPLD 催化的溶血磷脂酰胆碱和 FS-3 水解反应,并通过激活 LPA1、LPA2 触发钙动员、NFATc1 转位、Rho/ROCK 激活、Smad2/3 磷酸化及 c-Fos 表达,还可诱导类焦虑、类抑郁及运动减少表型,调控破骨细胞细胞骨架与存活能力,降低破骨细胞的骨吸收活性,驱动间充质干细胞向肌成纤维样细胞分化,并刺激转化生长因子-β1 和基质细胞衍生因子-1 的分泌,因此可用于焦虑症、抑郁症及卵巢癌的相关研究。

生物实验数据

生物活性 1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (MS-G09778), and GMP-grade small molecules can be used as ancillary reagents in cell therapy; 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule that inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3, activates LPA1 and LPA2 to trigger calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation, and c-Fos expression, induces anxiety-like, depression-like, and reduced locomotion phenotypes, regulates osteoclast cytoskeleton and survival, decreases osteoclast bone resorption activity, drives mesenchymal stem cell differentiation into myofibroblast-like cells, and stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1, making it useful for research on anxiety, depression, and ovarian cancer.
体外研究
(In Vitro)

1-Oleoyl lysophosphatidic acid sodium 在分光光度法、荧光分析实验检测中竞争性抑制纯化的牛血清溶血磷脂酶 D (lysoPLD) 活性,Ki 值为 9.6、1.2 μM。
1-Oleoyl lysophosphatidic acid sodium (GMP) (400 nM-10 μM) 可在原代大鼠和兔破骨细胞中诱导浓度依赖性的瞬时[Ca2+]i 升高,约 400 nM 即可使 50%的细胞产生反应,且该反应由偶联 Gi/o 的 LPA1/3 受体介导。
1-Oleoyl lysophosphatidic acid sodium (GMP) (5 μM) 可通过涉及 Rho 相关激酶的通路,诱导原代大鼠破骨细胞板状伪足持续回缩,并破坏外周肌动蛋白带。
1-Oleoyl lysophosphatidic acid sodium (0-5 μM; 3-18 h)通过 Gi/o 偶联的 LPA1 受体通路提高原代大鼠破骨细胞的存活率,抑制原代大鼠破骨细胞的凋亡,诱导原代兔破骨细胞中 NFATc1 的核转位。
1-Oleoyl lysophosphatidic acid sodium (5 μM; 5 min) 可通过 MEK1/2 依赖的通路在 RAW 264.7 来源的破骨细胞样细胞中诱导轻度的 ERK1/2 磷酸化。
1-Oleoyl lysophosphatidic acid sodium (0-10 μM; 0-96 h) 可通过依赖 LPA 受体、依赖 Smad2/3 的信号通路,诱导人脂肪组织来源间充质干细胞中 Smad2 和 Smad3 的延迟磷酸化及后续 α-平滑肌肌动蛋白的表达。
1-Oleoyl lysophosphatidic acid sodium (5 μM; 0-48 hours, 4 days) 可通过刺激自分泌 TGF-β1 分泌及后续的 Smad2 激活,诱导人脂肪组织来源间充质干细胞中 α-平滑肌肌动蛋白的表达。
1-Oleoyl lysophosphatidic acid sodium (0-20 μM; 0-48 h) 可通过依赖于 LPA 受体、依赖于 TGF-β1 的信号通路,以剂量和时间依赖的方式诱导人脂肪组织来源间充质干细胞中基质细胞衍生因子-1 (SDF-1) 的表达与分泌。
1-Oleoyl lysophosphatidic acid sodium (5 μM; 4 days) 可诱导人脂肪组织来源的间充质干细胞分化为肌成纤维细胞样细胞 (表达 α-平滑肌肌动蛋白和钙调蛋白,但不表达平滑肌肌球蛋白重链)。

ELISA Assay

Cell Line: RAW 264.7-derived osteoclast-like cells
Concentration: 5 μM
Incubation Time: 5 min
Result: Induced a small but significant increase in phospho-ERK1/2 levels.
Had effect blocked by 10 μM U0126.

Western Blot Analysis

Cell Line: human adipose tissue-derived mesenchymal stem cells (hADSCs)
Concentration: 0-10 μM (dose-response); 5 μM (time-course); 5 μM (Ki16425 pre-incubation group); 10 μM (Ki16425)
Incubation Time: 4 days (dose-response); 3-96 hours (time-course); 4 days (Ki16425 pre-incubation group)
Result: Increased α-SMA expression dose-dependently, with maximal increase at 5 μM after 4 days.
Increased α-SMA expression starting 48 hours after 5 μM treatment, with maximal levels at 96 hours.
Completely abolished the 5 μM-induced α-SMA expression when pre-incubated with 10 μM Ki16425.

Western Blot Analysis

Cell Line: human adipose tissue-derived mesenchymal stem cells (hADSCs)
Concentration: 5 μM (time-course); 5 μM (Ki16425 pre-incubation group); 10 μM (Ki16425); 10 μM (SIS3); siRNA transfection (Smad2/3); adenoviral Smad7 expression
Incubation Time: 0-96 hours (time-course); 4 days (inhibitor/siRNA/adenovirus groups)
Result: Induced delayed phosphorylation of Smad2 and Smad3, with maximal levels at 48 hours, sustained through 96 hours.
Completely abolished Smad2/3 phosphorylation when pre-incubated with 10 μM Ki16425.
Completely abrogated 5 μM-induced α-SMA expression and corresponding Smad phosphorylation after siRNA-mediated knockdown of Smad2 or Smad3.
Attenuated 5 μM-induced α-SMA expression and Smad3 phosphorylation (but not Smad2 phosphorylation) when pre-incubated with 10 μM SIS3.
Abrogated 5 μM-induced α-SMA expression and Smad2/3 phosphorylation after adenoviral overexpression of Smad7.

Western Blot Analysis

Cell Line: human adipose tissue-derived mesenchymal stem cells (hADSCs)
Concentration: 5 μM
Incubation Time: 4 days
Result: Increased expression of α-SMA and calponin in hADSCs.
Did not induce expression of smooth muscle myosin heavy chain (SM-MHC).
体内研究
(In Vivo)

1-Oleoyl lysophosphatidic acid sodium (0.4-2 μg/5 μL;i.c.v.;单次注射) 可呈剂量依赖性诱导大鼠产生类焦虑和类抑郁行为,可使 DPAG 区的 c-Fos 表达上调 94%。

Animal Model: Wistar rats (9-week-old male, 250-300 g)
Dosage: 0.4 μg/5 μL; 2 μg/5 μL
Administration: i.c.v.; single injection
Result: Reduced time spent in open arms by approximately 89% (2 μg dose, elevated plus-maze novelty condition); showed no significant effect on time spent in open arms (0.4 μg dose, elevated plus-maze novelty condition).
Reduced locomotor activity (crossings) by approximately 40% (2 μg dose, open-field test novelty condition); showed no significant effect on locomotor activity (0.4 μg dose, open-field test novelty condition).
Increased locomotor activity by approximately 180% (2 μg dose, open-field test habituation condition); showed no significant effect on locomotor activity (0.4 μg dose, open-field test habituation condition).
Reduced the percentage of rats that first entered the novel arm to chance levels (both doses, Y maze test); significantly reduced total time spent in the novel arm (0.4 μg dose, Y maze test); showed a near-significant reduction in total time spent in the novel arm (p=0.0558, 2 μg dose, Y maze test).
Increased immobility time by 75% (0.4 μg dose, forced swimming test); increased immobility time by 120% (2 μg dose, forced swimming test).
Increased c-Fos immunoreactivity in the dorsal periaqueductal gray matter (DPAG) by 94% (2 μg dose).

化学信息

分子量 458.50
分子式 C21H40NaO7P
CAS No. 325465-93-8
别名 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

储存&溶解度

溶解度信息
H2O: 14.71 mg/mL (32.08 mM), Sonication is recommended.
DMSO: Insoluble
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础